Literature DB >> 18285501

Protective heterologous immunity against fatal ehrlichiosis and lack of protection following homologous challenge.

Nagaraja R Thirumalapura1, Heather L Stevenson, David H Walker, Nahed Ismail.   

Abstract

The roles of antibodies and memory T cells in protection against virulent Ehrlichia have not been completely investigated. In this study, we addressed these issues by using murine models of mild and fatal ehrlichiosis caused by related monocytotropic Ehrlichia strains. Mice were primed with either Ehrlichia muris or closely related virulent ehrlichiae transmitted by Ixodes ovatus (IOE) ticks given intraperitoneally or intradermally. All groups were reinfected intraperitoneally, 30 days later, with a lethal high dose of IOE. Priming with E. muris, but not IOE, induced strong CD4+ and CD8+ memory type 1 T-cell responses, Ehrlichia-specific immunoglobulin G (IgG) antibodies, and persistent infection. Compared to IOE-primed mice, subsequent lethal IOE challenge of E. muris-primed mice, resulted in (i) 100% protection against lethal infection, (ii) strong Ehrlichia-specific secondary gamma interferon (IFN-gamma)-producing effector/effector memory CD4+ and CD8+ T-cell responses, (iii) enhanced secondary anti-ehrlichial antibody response, (iv) accelerated bacterial clearance, and (v) the formation of granulomas in the liver and lung. E. muris-primed mice challenged with IOE had lower levels of serum interleukin-1alpha (IL-1alpha), IL-6, and IL-10 compared to unprimed mice challenged with IOE. Interestingly, the fatal secondary response in IOE-primed mice correlated with (i) decline in the Ehrlichia-specific CD4+ and CD8+ type 1 responses, (ii) marked hepatic apoptosis and necrosis, and (iii) substantial bacterial clearance, suggesting that fatal secondary response is due to immune-mediated tissue damage. In conclusion, protection against fatal ehrlichial infection correlates with strong expansion of IFN-gamma-producing CD4+ and CD8+ effector memory type 1 T cells, which appear to be maintained in the presence of IgG antibodies and persistent infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285501      PMCID: PMC2346691          DOI: 10.1128/IAI.01293-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Class II-independent generation of CD4 memory T cells from effectors.

Authors:  S L Swain; H Hu; G Huston
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

3.  Animal model of fatal human monocytotropic ehrlichiosis.

Authors:  E A Sotomayor; V L Popov; H M Feng; D H Walker; J P Olano
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  New Ehrlichia species closely related to Ehrlichia chaffeensis isolated from Ixodes ovatus ticks in Japan.

Authors:  S Shibata; M Kawahara; Y Rikihisa; H Fujita; Y Watanabe; C Suto; T Ito
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Phylogenetic relationships of Anaplasma marginale and 'Ehrlichia platys' to other Ehrlichia species determined by GroEL amino acid sequences.

Authors:  X J Yu; X F Zhang; J W McBride; Y Zhang; D H Walker
Journal:  Int J Syst Evol Microbiol       Date:  2001-05       Impact factor: 2.747

6.  Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis.

Authors:  J S Li; E Yager; M Reilly; C Freeman; G R Reddy; A A Reilly; F K Chu; G M Winslow
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

7.  A conserved, transcriptionally active p28 multigene locus of Ehrlichia canis.

Authors:  J W McBride; X J Yu; D H Walker
Journal:  Gene       Date:  2000-08-22       Impact factor: 3.688

8.  T-Cell-independent humoral immunity is sufficient for protection against fatal intracellular ehrlichia infection.

Authors:  Constantine Bitsaktsis; Bisweswar Nandi; Rachael Racine; Katherine C MacNamara; Gary Winslow
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

9.  Migration and function of antigen-primed nonpolarized T lymphocytes in vivo.

Authors:  G Iezzi; D Scheidegger; A Lanzavecchia
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

10.  In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells.

Authors:  X Wang; T Mosmann
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  16 in total

Review 1.  Molecular and cellular pathobiology of Ehrlichia infection: targets for new therapeutics and immunomodulation strategies.

Authors:  Jere W McBride; David H Walker
Journal:  Expert Rev Mol Med       Date:  2011-01-31       Impact factor: 5.600

2.  Immunization with Ehrlichia P28 outer membrane proteins confers protection in a mouse model of ehrlichiosis.

Authors:  Patricia A Crocquet-Valdes; Nagaraja R Thirumalapura; Nahed Ismail; Xuejie Yu; Tais B Saito; Heather L Stevenson; Colette A Pietzsch; Sunil Thomas; David H Walker
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

3.  Liver Is a Generative Site for the B Cell Response to Ehrlichia muris.

Authors:  Nikita Trivedi; Florian Weisel; Shuchi Smita; Stephen Joachim; Muhamuda Kader; Aditya Radhakrishnan; Chris Clouser; Aaron M Rosenfeld; Maria Chikina; Francois Vigneault; Uri Hershberg; Nahed Ismail; Mark Jay Shlomchik
Journal:  Immunity       Date:  2019-11-12       Impact factor: 31.745

Review 4.  Progress and obstacles in vaccine development for the ehrlichioses.

Authors:  Jere W McBride; David H Walker
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Type I interferon contributes to noncanonical inflammasome activation, mediates immunopathology, and impairs protective immunity during fatal infection with lipopolysaccharide-negative ehrlichiae.

Authors:  Qin Yang; Heather L Stevenson; Melanie J Scott; Nahed Ismail
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

6.  Antigenic protein modifications in Ehrlichia.

Authors:  S Thomas; N Thirumalapura; E C Crossley; N Ismail; D H Walker
Journal:  Parasite Immunol       Date:  2009-06       Impact factor: 2.280

7.  Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis.

Authors:  Yubin Zhang; Vinh Thai; Amanda McCabe; Maura Jones; Katherine C MacNamara
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

8.  Strain and virulence diversity in the mouse pathogen Chlamydia muridarum.

Authors:  Kyle H Ramsey; Ira M Sigar; Justin H Schripsema; Cecele J Denman; Anne K Bowlin; Garry A S Myers; Roger G Rank
Journal:  Infect Immun       Date:  2009-05-26       Impact factor: 3.441

9.  Recombinant Ehrlichia P29 protein induces a protective immune response in a mouse model of ehrlichiosis.

Authors:  Nagaraja R Thirumalapura; Patricia A Crocquet-Valdes; Tais B Saito; Sunil Thomas; Jere W McBride; David H Walker
Journal:  Vaccine       Date:  2013-10-19       Impact factor: 3.641

10.  Persistent infection contributes to heterologous protective immunity against fatal ehrlichiosis.

Authors:  Nagaraja R Thirumalapura; Emily C Crossley; David H Walker; Nahed Ismail
Journal:  Infect Immun       Date:  2009-10-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.